View in EDS

Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO Trial.

Saved in:
Bibliographic Details
Title: Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO Trial.
Authors: Budde LE; City of Hope, Duarte, CA., Zhang H; Tianjin Medical University Cancer Institute, Tianjin, China., Kim WS; Samsung Medical Center, Seoul, Republic of Korea., Maruyama D; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan., Rego EM; Instituto D'Or de Pesquisa e Ensino, São Paulo, Brazil., Norasetthada L; Chiang Mai University, Chiang Mai, Thailand., Hong H; Si Chuan Cancer Hospital, Chengdu, China., Ozcan M; Ankara University School of Medicine, Ankara, Turkey., Jeon YW; Yeouido St Mary's Hospital, Seoul, Republic of Korea., Leão Cordeiro de Farias D; Hospital Beneficência Portuguesa de São Paulo, São Paulo, Brazil., Fogliatto LM; Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil., Pavlovsky A; Fundaleu, Buenos Aires, Argentina., Goto H; Department of Hematology, Hokkaido University Hospital, Sapporo, Japan., Olszewski AJ; Brown University, Providence, RI., Shah N; Tampa General Hospital Cancer Institute, Tampa, FL., Hu B; Atrium Health Levine Cancer Institute and Wake Forest School of Medicine, Charlotte, NC., Yin S; Genentech, Inc, South San Francisco, CA., Wu H; Genentech, Inc, South San Francisco, CA., To I; Genentech, Inc, South San Francisco, CA., Ead WS; Genentech, Inc, South San Francisco, CA., Ashby J; Genentech, Inc, South San Francisco, CA., Janousek M; F. Hoffmann-La Roche Ltd, Basel, Switzerland., Pham S; Hoffmann-La Roche Ltd, Mississauga, ON, Canada., Wang J; Genentech, Inc, South San Francisco, CA., Kwan A; Genentech, Inc, South San Francisco, CA., Batlevi CL; Genentech, Inc, South San Francisco, CA., Wei MC; Genentech, Inc, South San Francisco, CA., Westin J; MD Anderson Cancer Center, Houston, TX.
Source: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2025 Dec 20; Vol. 43 (36), pp. 3799-3811. Date of Electronic Publication: 2025 Oct 02.
Publication Type: Journal Article; Clinical Trial, Phase III; Randomized Controlled Trial; Multicenter Study; Research Support, Non-U.S. Gov't
Journal Info: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41037766
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO Trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Budde+LE%22">Budde LE</searchLink>; City of Hope, Duarte, CA.<br /><searchLink fieldCode="AU" term="%22Zhang+H%22">Zhang H</searchLink>; Tianjin Medical University Cancer Institute, Tianjin, China.<br /><searchLink fieldCode="AU" term="%22Kim+WS%22">Kim WS</searchLink>; Samsung Medical Center, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Maruyama+D%22">Maruyama D</searchLink>; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.<br /><searchLink fieldCode="AU" term="%22Rego+EM%22">Rego EM</searchLink>; Instituto D'Or de Pesquisa e Ensino, São Paulo, Brazil.<br /><searchLink fieldCode="AU" term="%22Norasetthada+L%22">Norasetthada L</searchLink>; Chiang Mai University, Chiang Mai, Thailand.<br /><searchLink fieldCode="AU" term="%22Hong+H%22">Hong H</searchLink>; Si Chuan Cancer Hospital, Chengdu, China.<br /><searchLink fieldCode="AU" term="%22Ozcan+M%22">Ozcan M</searchLink>; Ankara University School of Medicine, Ankara, Turkey.<br /><searchLink fieldCode="AU" term="%22Jeon+YW%22">Jeon YW</searchLink>; Yeouido St Mary's Hospital, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Leão+Cordeiro+de+Farias+D%22">Leão Cordeiro de Farias D</searchLink>; Hospital Beneficência Portuguesa de São Paulo, São Paulo, Brazil.<br /><searchLink fieldCode="AU" term="%22Fogliatto+LM%22">Fogliatto LM</searchLink>; Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.<br /><searchLink fieldCode="AU" term="%22Pavlovsky+A%22">Pavlovsky A</searchLink>; Fundaleu, Buenos Aires, Argentina.<br /><searchLink fieldCode="AU" term="%22Goto+H%22">Goto H</searchLink>; Department of Hematology, Hokkaido University Hospital, Sapporo, Japan.<br /><searchLink fieldCode="AU" term="%22Olszewski+AJ%22">Olszewski AJ</searchLink>; Brown University, Providence, RI.<br /><searchLink fieldCode="AU" term="%22Shah+N%22">Shah N</searchLink>; Tampa General Hospital Cancer Institute, Tampa, FL.<br /><searchLink fieldCode="AU" term="%22Hu+B%22">Hu B</searchLink>; Atrium Health Levine Cancer Institute and Wake Forest School of Medicine, Charlotte, NC.<br /><searchLink fieldCode="AU" term="%22Yin+S%22">Yin S</searchLink>; Genentech, Inc, South San Francisco, CA.<br /><searchLink fieldCode="AU" term="%22Wu+H%22">Wu H</searchLink>; Genentech, Inc, South San Francisco, CA.<br /><searchLink fieldCode="AU" term="%22To+I%22">To I</searchLink>; Genentech, Inc, South San Francisco, CA.<br /><searchLink fieldCode="AU" term="%22Ead+WS%22">Ead WS</searchLink>; Genentech, Inc, South San Francisco, CA.<br /><searchLink fieldCode="AU" term="%22Ashby+J%22">Ashby J</searchLink>; Genentech, Inc, South San Francisco, CA.<br /><searchLink fieldCode="AU" term="%22Janousek+M%22">Janousek M</searchLink>; F. Hoffmann-La Roche Ltd, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Pham+S%22">Pham S</searchLink>; Hoffmann-La Roche Ltd, Mississauga, ON, Canada.<br /><searchLink fieldCode="AU" term="%22Wang+J%22">Wang J</searchLink>; Genentech, Inc, South San Francisco, CA.<br /><searchLink fieldCode="AU" term="%22Kwan+A%22">Kwan A</searchLink>; Genentech, Inc, South San Francisco, CA.<br /><searchLink fieldCode="AU" term="%22Batlevi+CL%22">Batlevi CL</searchLink>; Genentech, Inc, South San Francisco, CA.<br /><searchLink fieldCode="AU" term="%22Wei+MC%22">Wei MC</searchLink>; Genentech, Inc, South San Francisco, CA.<br /><searchLink fieldCode="AU" term="%22Westin+J%22">Westin J</searchLink>; MD Anderson Cancer Center, Houston, TX.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%228309333%22">Journal of clinical oncology : official journal of the American Society of Clinical Oncology</searchLink> [J Clin Oncol] 2025 Dec 20; Vol. 43 (36), pp. 3799-3811. <i>Date of Electronic Publication: </i>2025 Oct 02.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase III; Randomized Controlled Trial; Multicenter Study; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Society+of+Clinical+Oncology%22">American Society of Clinical Oncology </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>8309333 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1527-7755 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%220732183X%22">0732183X </searchLink><i>NLM ISO Abbreviation: </i>J Clin Oncol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41037766
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1200/JCO-25-01957
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 3799
    Titles:
      – TitleFull: Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO Trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Budde LE
      – PersonEntity:
          Name:
            NameFull: Zhang H
      – PersonEntity:
          Name:
            NameFull: Kim WS
      – PersonEntity:
          Name:
            NameFull: Maruyama D
      – PersonEntity:
          Name:
            NameFull: Rego EM
      – PersonEntity:
          Name:
            NameFull: Norasetthada L
      – PersonEntity:
          Name:
            NameFull: Hong H
      – PersonEntity:
          Name:
            NameFull: Ozcan M
      – PersonEntity:
          Name:
            NameFull: Jeon YW
      – PersonEntity:
          Name:
            NameFull: Leão Cordeiro de Farias D
      – PersonEntity:
          Name:
            NameFull: Fogliatto LM
      – PersonEntity:
          Name:
            NameFull: Pavlovsky A
      – PersonEntity:
          Name:
            NameFull: Goto H
      – PersonEntity:
          Name:
            NameFull: Olszewski AJ
      – PersonEntity:
          Name:
            NameFull: Shah N
      – PersonEntity:
          Name:
            NameFull: Hu B
      – PersonEntity:
          Name:
            NameFull: Yin S
      – PersonEntity:
          Name:
            NameFull: Wu H
      – PersonEntity:
          Name:
            NameFull: To I
      – PersonEntity:
          Name:
            NameFull: Ead WS
      – PersonEntity:
          Name:
            NameFull: Ashby J
      – PersonEntity:
          Name:
            NameFull: Janousek M
      – PersonEntity:
          Name:
            NameFull: Pham S
      – PersonEntity:
          Name:
            NameFull: Wang J
      – PersonEntity:
          Name:
            NameFull: Kwan A
      – PersonEntity:
          Name:
            NameFull: Batlevi CL
      – PersonEntity:
          Name:
            NameFull: Wei MC
      – PersonEntity:
          Name:
            NameFull: Westin J
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 20
              M: 12
              Text: 2025 Dec 20
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 1527-7755
          Numbering:
            – Type: volume
              Value: 43
            – Type: issue
              Value: 36
          Titles:
            – TitleFull: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
              Type: main
ResultId 1